Hikma Pharmaceuticals Plc Director/PDMR Shareholding (5265E)
28 Febbraio 2020 - 1:23PM
UK Regulatory
TIDMHIK
RNS Number : 5265E
Hikma Pharmaceuticals Plc
28 February 2020
Hikma Pharmaceuticals PLC
Notification and public disclosure of transactions by persons
discharging managerial responsibilities
Said Darwazah
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Said Darwazah
2 Reason for the notification
a) Position/status Executive Chairman
b) Initial notification Initial notification
/Amendment
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
a) Description of Description: Ordinary shares of 10 pence each
the financial ID Code: GB00B0LCW083
instrument, type
of instrument
and identification
code
b) Nature of the Pledge by Darhold Limited of 2,000,000 Ordinary
transaction Shares of 10 pence each in Hikma Pharmaceuticals
PLC in favour of J.P. Morgan (Suisse) SA. The
Executive Chairman is a director of and shareholder
in Darhold Limited with an equity interest of
21.99%.
c) Price(s) and Price(s): GBP0.00p
volume(s) Volume(s): 2,000,000
d) Aggregated information Aggregated volume: 2,000,000
Price: GBP0.00p
e) Date of the transaction 28 February 2020
f) Place of the Amman
transaction
Mazen Darwazah
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Mazen Darwazah
2 Reason for the notification
a) Position/status Executive Vice Chairman
b) Initial notification Initial notification
/Amendment
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
a) Description of Description: Ordinary shares of 10 pence each
the financial ID Code: GB00B0LCW083
instrument, type
of instrument
and identification
code
b) Nature of the Pledge by Darhold Limited of 2,000,000 Ordinary
transaction Shares of 10 pence each in Hikma Pharmaceuticals
PLC in favour of J.P. Morgan (Suisse) SA. The
Executive Vice Chairman is a director of and
shareholder in Darhold Limited with an equity
interest of 11.08%.
c) Price(s) and Price(s): GBP0.00p
volume(s) Volume(s): 2,000,000
d) Aggregated information Aggregated volume: 2,000,000
Price: GBP0.00p
e) Date of the transaction 28 February 2020
f) Place of the Amman
transaction
Mohammed 'Ali' Al-Husry
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Mohammed 'Ali' Al-Husry
2 Reason for the notification
a) Position/status Non-Executive Director
b) Initial notification Initial notification
/Amendment
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
a) Description of Description: Ordinary shares of 10 pence each
the financial ID Code: GB00B0LCW083
instrument, type
of instrument
and identification
code
b) Nature of the Pledge by Darhold Limited of 2,000,000 Ordinary
transaction Shares of 10 pence each in Hikma Pharmaceuticals
PLC in favour of J.P. Morgan (Suisse) SA. The
Non-Executive Director is a director of and
shareholder in Darhold Limited with an equity
interest of 8.13%.
c) Price(s) and Price(s): GBP0.00p
volume(s) Volume(s): 2,000,000
d) Aggregated information Aggregated volume: 2,000,000
Price: GBP0.00p
e) Date of the transaction 28 February 2020
f) Place of the Amman
transaction
Peter Speirs
Company Secretary, responsible for releasing this
announcement
+44 (0) 20 7399 2760
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHBDGDDGDDDGGI
(END) Dow Jones Newswires
February 28, 2020 07:23 ET (12:23 GMT)
Grafico Azioni Hikma Pharmaceuticals (LSE:HIK)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Hikma Pharmaceuticals (LSE:HIK)
Storico
Da Apr 2023 a Apr 2024